A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma
- 3 March 2022
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (5) , E486-E494
Abstract
We aimed to develop a new risk stratification tool to predict freedom from progression (FFP) for newly diagnosed advanced classical Hodgkin lymphoma (cHL). We collected data from 386 patients with advanced cHL diagnosed between December 8, 2000 and October 29, 2018, and treated with curative intent with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or an ABVD-equivalent regimen. Cases were randomly divided into training and validation cohorts at a ratio of 7:3. The new model was constructed based on the results of Cox proportional hazards model in the training cohort. Comparisons of discrimination between the new model and other models in the training and validation cohorts for FFP prediction were measured by time-dependent area under curve (tAUC) and Harrell's C-index. Calibration plots were constructed to compare the consistency between the predicted and observed estimates of survival probability for the new model in the training and validation cohorts. The new model (IPSPLR) composed of International Prognostic Score (IPS)-3 and platelet/lymphocyte ratio (PLR) provided four distinct risk groups. The IPSPLR showed better discriminative ability when compared with IPS-3 and IPS-7. The AUC of IPSPLR was consistently higher than that of IPS-3 and IPS-7 between 12 and 120 months. The C-index of the IPSPLR was higher than that of IPS-7 and IPS-3. The calibration plots showed an excellent agreement between the IPSPLR-predicted and observed estimates of 5-year FFP. The IPSPLR is an easily used tool for FFP prediction for newly diagnosed advanced cHL. Validation of this tool in other large datasets is needed.Keywords
This publication has 40 references indexed in Scilit:
- Paraneoplastic Thrombocytosis in Ovarian CancerNew England Journal of Medicine, 2012
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaHaematologica, 2011
- Contribution of platelets to tumour metastasisNature Reviews Cancer, 2011
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Journal of Clinical Oncology, 2009
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2007
- X-TileClinical Cancer Research, 2004
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998